PRLD$4.43
$4.61
Chart
Performance
Key Stats
AI PRLD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldPrelude Therapeutics (PRLD) shows potential in the precision oncology space but faces significant headwinds in terms of profitability and consistent revenue. While the company has a clear thematic driver in cancer drug development, its financial performance and market valuation suggest a holding pattern rather than a strong buy or sell recommendation at this time.
Thematic
Prelude Therapeutics is positioned in the high-growth, high-impact field of precision oncology. Its focus on developing novel therapies for underserved patient populations, particularly those with specific genetic mutations like SMARCA2 loss, aligns with major trends in targeted cancer treatment and personalized medicine. The company's pipeline addresses significant unmet medical needs.
Fundamental
Prelude Therapeutics exhibits a weak fundamental profile primarily due to its clinical-stage nature, resulting in no revenue generation and significant net losses. While it has a substantial cash reserve and manageable debt, the lack of current profitability and reliance on future drug approvals present considerable financial risk. Valuation metrics like P/E and P/S are not applicable or highly negative due to negative earnings.
Technical
Technical indicators for Prelude Therapeutics (PRLD) show mixed signals. The stock has experienced significant volatility, with a sharp decline over the past year, but has seen some recovery in recent short-term periods. Current trading action suggests it is consolidating, with support levels to watch.
| Factor | Score |
|---|---|
| Precision Oncology | 85 |
| Biotechnology Innovation | 70 |
| Market Adoption of Targeted Therapies | 80 |
| Regulatory Landscape (FDA Approvals) | 60 |
| Competitive Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 80 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 60 |
| Moving Averages | 40 |
| Support & Resistance | 55 |
| Volume | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Short-Term Momentum
The stock has shown positive performance over the past 5 days (+8.77%) and 1 month (+18.47%), indicating current investor interest.
Increased Trading Volume
The average 30-day volume (77,190) is significantly lower than the current volume (187,033), which could signal increased investor activity or interest, though interpretation depends on the context of news or events.
Bearish Points (10)
Significant Decline from 52-Week High
The current price ($0.93) is significantly lower than its 52-week range high of $6.8, representing a substantial loss from its peak.
Negative Long-Term Performance
The stock has experienced significant negative returns over the past 6 months (-17.7%), year-to-date (-25.6%), and 1 year (-82.94%), indicating a strong downtrend.
Calendar
August 2025
11
Next Earnings Date
H: $-0.43
A: $-0.43
L: $-0.43
Profile
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Seasonals
Price Target
3.75 USD
The 39 analysts offering 1 year price forecasts for PRLD have a max estimate of 5.00 and a min estimate of 1.00.